focus -WSS

focus

author：hotspot 2025-09-27 23:01:28 - browse：65838

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Amid AI frenzy, a top HHS official's quest to create safeguards

Wikipedia

WSS

John Green on his newest strategy for fighting tuberculosis

US jobless claims fall again as labor market continues to flash strength

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Readout Newsletter: CAR

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

President Biden's budget: Here's what you might have missed

hotspot

focus

knowledge

Bright Health sells Medicare Advantage business to Molina

As AI in medicine takes off, can 'human in the loop' prevent harm?

BioMarin wins approval for gene therapy to treat hemophilia A

Sanders wants to replace patents with prizes for drug inventions

After affirmative action ruling, medical educators look to 'holistic review'

WuXi out of biotech trade group, U.S. and China relations to blame

Dobbs anniversary: the lost opportunity of abortion as health care

Scientists grapple with ethics of stem cell research

Hollywood unions extend contract negotiations for actors

Are infertility treatments 'essential' during the Covid

entertainment

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

HHS secretary Becerra pressed on Change HealthCare cyberattack

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Scientists grapple with ethics of stem cell research

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Wikipedia

Wikipedia

hotspot

Wikipedia